Eli Anderson, MD
Psychiatry · Houston, TXNPI 1053342634
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 328 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,362 and has fallen 52.2% since, to $1,129 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 328 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$818
- Alkermes, Inc.$602
- Sunovion Pharmaceuticals Inc.$444
- plus $2K from 16 others
What the payments were for
- Food & beverage$8,072100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 73 | $1,866 |
| Johnson & Johnson | 71 | $1,669 |
| Teva Pharmaceuticals USA, Inc. | 47 | $1,126 |
| Otsuka America Pharmaceutical, Inc. | 35 | $818 |
| Alkermes, Inc. | 20 | $602 |
| Sunovion Pharmaceuticals Inc. | 19 | $444 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $294 |
| Neurocrine Biosciences, Inc. | 10 | $225 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $209 |
| Vanda Pharmaceuticals Inc. | 8 | $186 |
| Ironshore Pharmaceuticals Inc. | 2 | $146 |
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| Lundbeck LLC | 5 | $91 |
| Axsome Therapeutics, Inc. | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Indivior Inc. | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| Eisai Inc. | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Medline Industries LP | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$745
- LYBALVI$457
- AUSTEDO$234
- REXULTI$230
- Jornay PM 20mg capsules (Bottle of 100)$126
- ONIVYDE$125
- LATUDA$124
- INVEGA SUSTENNA$104
- INVEGA TRINZA$104
- SPRAVATO$102
How this compares
$8,072 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 33 | $336,052 |
| Invega SustennaPaliperidone Palmitate | 34 | $104,093 |
| VraylarCariprazine Hcl | 63 | $93,843 |
| RexultiBrexpiprazole | 34 | $49,649 |
| TrintellixVortioxetine Hydrobromide | 17 | $9,523 |
| Lisdexamfetamine Dimesylate | 22 | $6,241 |
| Lurasidone Hcl | 24 | $5,185 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 48 | $4,271 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $3,772 |
| Aripiprazole | 51 | $3,702 |
| Atomoxetine Hcl | 16 | $3,537 |
| Paliperidone ErPaliperidone | 12 | $2,879 |
| Bupropion XlBupropion Hcl | 59 | $2,260 |
| Oxcarbazepine | 39 | $2,227 |
| Chlorpromazine Hcl | 22 | $1,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $225 | $336,05233 claims |
| Johnson & JohnsonInvega Sustenna | $1,669 | $104,09334 claims |
| AbbVieVraylar | $1,866 | $93,84363 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $818 | $49,64934 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $294 | $13,29528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.